Institute of Hematology & Blood Diseases Hospital, China: Leukemia trials

The registry lists 36 Leukemia studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 20 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 10Phase 2 16Phase 3 3Phase 4 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
• National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic LeukemiaRecruitingNCT07019766
• Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute LeukemiaNot yet recruitingNCT06955858Not applicable
• Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms PatientsNot yet recruitingNCT06900088Phase 2
• A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06880354Phase 1
• Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingNCT06783790Phase 2
• Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALLNot yet recruitingNCT06658925Phase 2
• Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid LeukemiaNot yet recruitingNCT06643195Not applicable
• Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
• Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingNCT06608732Phase 2
• Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaRecruitingNCT06608342Phase 2
• the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT06461091
• VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
• Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid LeukemiaRecruitingNCT05519384Early Phase 1
• Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLLRecruitingNCT04453345Phase 2/3
• A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyTerminatedNCT06449482Phase 1/2
• Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid LeukemiaCompletedNCT05941585Not applicable
• Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedNCT05676710Phase 1
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaActive, not recruitingNCT05356169Phase 2/3
• Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaStatus unknownNCT05335226Not applicable
• A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Phase 1
• Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedNCT05071482Phase 4
• Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid LeukemiaActive, not recruitingNCT04415008Phase 2
• CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Early Phase 1
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
• The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
• Efficacy and Safety of Chidamide in CBF LeukemiaActive, not recruitingNCT03031262Phase 1/2
• CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1
• Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 2